Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Sumitaka, Hasegawa"'
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract The aim of this work is to estimate the biological effect of targeted radionuclide therapy using Cu-64, which is a well-known Auger electron emitter. To do so, we evaluate the absorbed dose of emitted particles from Cu-64 using the Geant4-DN
Externí odkaz:
https://doaj.org/article/931ab97c338c428f87ec954dd48730f0
Autor:
Yohei Kawasaki, Makoto Hori, Tadami Fujiwara, Hideki Hanaoka, Makio Shozu, Yasuhisa Fujii, Michiko Hanawa, Hirokazu Usui, Masaru Wakatsuki, Tomoya Kurokawa, Hiroshi Tsuji, Kazuko Suzuki, Noriyuki Okonogi, Kazutoshi Murata, Yoko Hattori, Kyoko Tsuyuki, Sumitaka Hasegawa, Shigeru Yamada
Publikováno v:
BMJ Open, Vol 12, Iss 3 (2022)
Introduction Concurrent chemoradiotherapy is considered the standard treatment strategy for locally advanced cervical cancer. Most recent reports indicate that patients with bulky tumours or adenocarcinoma subtypes have poorer local control. Carbon-i
Externí odkaz:
https://doaj.org/article/892ad548f96148c3a5cd2268922645dc
Autor:
Usui, Noriyuki Okonogi, Kazutoshi Murata, Shigeru Yamada, Yuji Habu, Makoto Hori, Tomoya Kurokawa, Yosuke Inaba, Tadami Fujiwara, Yasuhisa Fujii, Michiko Hanawa, Yohei Kawasaki, Yoko Hattori, Kazuko Suzuki, Kyoko Tsuyuki, Masaru Wakatsuki, Masashi Koto, Sumitaka Hasegawa, Hitoshi Ishikawa, Hideki Hanaoka, Makio Shozu, Hiroshi Tsuji, Hirokazu
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 13; Pages: 10565
We conducted a phase Ib study to examine the safety of a combination of carbon-ion RT (CIRT) with durvalumab (MEDI4736; AstraZeneca) in patients with locally advanced cervical cancer. This was an open-label, single-arm study with a modified 3 + 3 des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::49cca5feb6f5d38a2e71c3b4edc475d1
Autor:
Li, Huizi, Sumitaka, Hasegawa
Publikováno v:
Nuclear Medicine Communications. 43(7):763-769
Objectives: The 111In-labeled anti-HER2 antibody trastuzumab modified with a nuclear-localizing sequence (NLS) peptide (111In-trastuzumab-NLS) is a radiopharmaceutical candidate for Auger electron radioimmunotherapy (AE-RIT). However, in vivo action
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::c452f9e9232c19e67cdca4256fe8c13d
https://repo.qst.go.jp/records/86070
https://repo.qst.go.jp/records/86070
Autor:
Satoshi Kodaira, Huizi Keiko Li, Teruaki Konishi, Hisashi Kitamura, Mieko Kurano, Sumitaka Hasegawa
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0178472 (2017)
Recently, 211At has received increasing attention as a potential radionuclide for cancer radioimmunotherapy. It is a α-particle emitter, which is extremely effective against malignant cells. We demonstrate a method to verify the efficiency of 211At-
Externí odkaz:
https://doaj.org/article/919a22f7c13244a3a81bd2fc8a6a07f7
Publikováno v:
International journal of radiation oncology, biology, physics. 111(1):260-271
Purpose: Autophagy and cell-cycle checkpoints act in concert to confer cellular radioresistance. We investigated the functional interaction between radiation-induced autophagy and G2 checkpoint activation in highly radioresistant human pancreatic duc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::8a93a4eb86663013d045044409b5fdf6
https://repo.qst.go.jp/records/82949
https://repo.qst.go.jp/records/82949
Autor:
Ryoichi, Hirayama, Atsushi, Ito, Akiko, Uzawa, Yoshitaka, Matsumoto, Miho, Noguchi, Li, Huizi, Motofumi, Suzuki, Koichi, Ando, Ryuichi, Okayasu, Sumitaka, Hasegawa, Yoshiya, Furusawa
Publikováno v:
Radiation Research. 195(5):441-451
We examined lethal damages of X-rays induced by direct and indirect actions, in terms of DSB repair susceptibility using two kinds of repair deficient Chinese hamster ovary (CHO) cell lines. These CHO mutants (51D1 and xrs6) are genetically deficient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::255fad171d2bd4dd1a82d377209480a8
https://repo.qst.go.jp/records/82286
https://repo.qst.go.jp/records/82286
Autor:
Satoshi Kodaira, Kotaro Nagatsu, Huizi Keiko Li, Tamon Kusumoto, Yukie Morokoshi, Hiroaki Kanda, Katsuyuki Minegishi, Sumitaka Hasegawa
Publikováno v:
Journal of Nuclear Medicine. 62:1468-1474
A liver metastasis from a primary gastric cancer (LMGC) is relatively common and results in an extremely poor prognosis due to a lack of effective therapeutics. We here demonstrate in a clinically relevant mouse model that an α-particle radioimmunot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7597d18f020f2c6a1023a1f3d9b3bcf
https://doi.org/10.2967/jnumed.120.249300
https://doi.org/10.2967/jnumed.120.249300
Autor:
Li, Huizi, Yukie, Morokoshi, Satoshi, Kodaira, Tamon, Kusumoto, Katsuyuki, Minegishi, Hiroaki, Kanda, Kotaro, Nagatsu, Sumitaka, Hasegawa
Publikováno v:
Journal of nuclear medicine. 62(10):1468-1474
A liver metastasis from a primary gastric cancer (LMGC) is relatively common and results in an extremely poor prognosis due to a lack of effective therapeutics. We here demonstrate in a clinically-relevant mouse model that an α-radioimmunotherapy (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::ee59c6ba86e1b13f671444283cb2daac
https://repo.qst.go.jp/records/81792
https://repo.qst.go.jp/records/81792
Autor:
Huizi Keiko Li, Sumitaka Hasegawa
Publikováno v:
Nuclear medicine communications. 43(7)
The 111In-labeled anti-HER2 antibody trastuzumab modified with a nuclear-localizing sequence (NLS) peptide (111In-trastuzumab-NLS) is a radiopharmaceutical candidate for Auger electron radioimmunotherapy (AE-RIT). However, in-vivo action of 111In-tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e04366fb78a2e682dfccd3c10ac0949
https://pubmed.ncbi.nlm.nih.gov/35506286
https://pubmed.ncbi.nlm.nih.gov/35506286